A Phase I Dose-Escalation Study to Investigate the Safety and Immunogenicity of the Fusion Protein Recombinant Influenza A (HAC1) Vaccine Derived From Influenza A/California/04/09 (H1N1) in Healthy Adults

Trial Profile

A Phase I Dose-Escalation Study to Investigate the Safety and Immunogenicity of the Fusion Protein Recombinant Influenza A (HAC1) Vaccine Derived From Influenza A/California/04/09 (H1N1) in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions
  • Sponsors Fraunhofer USA Center for Molecular Biotechnology
  • Most Recent Events

    • 11 Oct 2013 Results published in Vaccine.
    • 21 Mar 2012 A manuscript is under preparation to be published in a peer-reviewed journal, according to a Fraunhofer USA Center for Molecular Biotechnology media release.
    • 21 Mar 2012 Final results published in a Fraunhofer USA Center for Molecular Biotechnology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top